<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35392963</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-6215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Trials</Title>
          <ISOAbbreviation>Trials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial.</ArticleTitle>
        <Pagination>
          <StartPage>266</StartPage>
          <MedlinePgn>266</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">266</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-06214-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Improving contractility in heart failure with reduced ejection fraction (HFrEF) has resurfaced as a potential treatment goal. Inotropic therapy is now better understood through its underlying mechanism as opposed to the observed effect of increasing contractility. Calcitropes are a subgroup of inotropes that largely depend on the stimulation of adenylyl cyclase to transform ATP into cyclic adenosine monophosphate (cAMP). At least two clinically relevant calcitropes-istaroxime and probenecid-improve contractility through an increase in systolic intracellular calcium without activating cAMP production. Probenecid, which has been safely used clinically for decades in non-cardiac conditions, has recently been identified as an agonist of the transient receptor potential vanilloid 2 channel. Translational studies have shown that it improves calcium cycling and contractility without activating noxious pathways associated with cAMP-dependent calcitropes and can improve cardiac function in patients with HFrEF.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The Re-Prosper-HF study (Repurposing Probenecid for the Treatment of Heart Failure with Reduced Ejection Fraction) is a three-site double-blinded randomized-controlled trial that will test the hypothesis that probenecid can improve cardiac function in patients with HFrEF. Up to 120 patients will be randomized in this double-blind, placebo-controlled study that will assess whether oral probenecid administered at 1 g orally twice per day for 180 days in patients with NYHA II-III HFrEF improves systolic function (aim 1), functional status (aim 2), and self-reported health status (aim 3).</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Findings from this study will provide data informing its use for improving symptomatology in patients with HFrEF as well as exploratory data for outcomes such as hospital admission rates.</AbstractText>
          <AbstractText Label="TRIAL TEGISTRATION" NlmCategory="UNASSIGNED">The Re-Prosper HF Study (Re-Prosper HF) is registered on ClinicalTrials.gov with the identifier as NCT04551222. Registered on 9 September 2020.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rubinstein</LastName>
            <ForeName>Jack</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-8811-1551</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Medicine, Cincinnati Veterans Affairs Medical Center, 3200 Vine St, Cincinnati, OH, 45220, USA. Jack.rubinstein@va.gov.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Cardiovascular Diseases, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA. Jack.rubinstein@va.gov.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robbins</LastName>
            <ForeName>Nathan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Ohio University, Heritage College of Osteopathic Medicine, Athens, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evans</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Service and Center of Innovation for Long Term Services &amp; Support, Providence Veterans Affairs Medical Center, Providence, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foster</LastName>
            <ForeName>Gabrielle</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts Veterans Epidemiology Research and Information Center and Medical Service, VA Boston Healthcare System, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mcconeghy</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Providence Veterans Affairs Medical Center, Providence, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onadeko</LastName>
            <ForeName>Toluwalope</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Veterans Affairs Medical Center, Cincinnati, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bunke</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Research, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parent</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Innovation for Long Term Services &amp; Support, Providence Veterans Affairs Medical Centers, Providence, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Jacob</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiology Section, VA Boston Healthcare System, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Brigham &amp; Women's Hospital, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Wen-Chih</ForeName>
            <Initials>WC</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Service and Center of Innovation for Long Term Services &amp; Support, Providence Veterans Affairs Medical Center, Providence, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Alpert Medical School, Providence, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology, Brown University, Providence, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT04551222</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>I01 CX001968</GrantID>
            <Acronym>CX</Acronym>
            <Agency>CSRD VA</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Trials</MedlineTA>
        <NlmUniqueID>101263253</NlmUniqueID>
        <ISSNLinking>1745-6215</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>PO572Z7917</RegistryNumber>
          <NameOfSubstance UI="D011339">Probenecid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011339" MajorTopicYN="N">Probenecid</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018487" MajorTopicYN="Y">Ventricular Dysfunction, Left</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Contractility</Keyword>
        <Keyword MajorTopicYN="N">Heart failure</Keyword>
        <Keyword MajorTopicYN="N">Inotropy</Keyword>
        <Keyword MajorTopicYN="N">Probenecid</Keyword>
      </KeywordList>
      <CoiStatement>Dr Rubinstein is a founding member of TRP therapeutics and has not received any fees, salary, or honoraria from this venture. He is also a founding member and board member of CinTRYP LLC from which he is currently defunct, in the past he received honoraria and royalties. He will not have access to the study data at any point prior to unblinding. All other authors have no disclosures to note.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35392963</ArticleId>
        <ArticleId IdType="pmc">PMC8991789</ArticleId>
        <ArticleId IdType="doi">10.1186/s13063-022-06214-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s13063-022-06214-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, Aragam J, Benjamin EJ, Larson MG. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11(1):1-11. 10.1016/j.jcmg.2017.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5756128</ArticleId>
            <ArticleId IdType="pubmed">28917679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parizo JT, Kohsaka S, Sandhu AT, Patel J, Heidenreich PA. Trends in readmission and mortality rates following heart failure hospitalization in the Veterans Affairs Health Care System from 2007 to 2017. JAMA Cardiol. 2020;5(9):1042–1047. doi: 10.1001/jamacardio.2020.2028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2020.2028</ArticleId>
            <ArticleId IdType="pmc">PMC7301300</ArticleId>
            <ArticleId IdType="pubmed">32936253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams KF, Jr, Rosano GMC, Lancellotti P. Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week. J Am Coll Cardiol. 2019;73(18):2345–2353. doi: 10.1016/j.jacc.2019.02.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2019.02.051</ArticleId>
            <ArticleId IdType="pubmed">31072579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015;16(12):29060–29068. doi: 10.3390/ijms161226147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms161226147</ArticleId>
            <ArticleId IdType="pmc">PMC4691094</ArticleId>
            <ArticleId IdType="pubmed">26690127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468–1475. doi: 10.1056/NEJM199111213252103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199111213252103</ArticleId>
            <ArticleId IdType="pubmed">1944425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carubelli V, Zhang Y, Metra M. et al; Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. Eur J Heart Fail. 2020;22(9):1684–1693. doi: 10.1002/ejhf.1743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.1743</ArticleId>
            <ArticleId IdType="pubmed">31975496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, Imaizumi Y. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res. 2003;93(9):829–838. doi: 10.1161/01.RES.0000097263.10220.0C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000097263.10220.0C</ArticleId>
            <ArticleId IdType="pubmed">14512441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch SE, Gao X, Haar L, Jiang M, Lasko VM, Robbins N, Cai W, Brokamp C, Varma P, Tranter M, Liu Y, Ren X, Lorenz JN, Wang HS, Jones WK, Rubinstein J. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012;53(1):134–144. doi: 10.1016/j.yjmcc.2012.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2012.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC3372642</ArticleId>
            <ArticleId IdType="pubmed">22561103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch SE, Tranter M, Robbins N, Luther K, Singh U, Jiang M, Ren X, Tee T, Smith L, Varma P, Jones WK, Rubinstein J. Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model. J Cardiovasc Pharmacol Ther. 2013;18(3):280–289. doi: 10.1177/1074248412469299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1074248412469299</ArticleId>
            <ArticleId IdType="pmc">PMC4365873</ArticleId>
            <ArticleId IdType="pubmed">23241275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onusko E, McDermott MR, Robbins N, et al.  Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy. PLoS One. 2020;15(3):e0230386. doi: 10.1371/journal.pone.0230386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0230386</ArticleId>
            <ArticleId IdType="pmc">PMC7100971</ArticleId>
            <ArticleId IdType="pubmed">32218573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Connor B, Robbins N, Koch SE, Rubinstein J. TRPV2 channel-based therapies in the cardiovascular field. Molecular underpinnings of clinically relevant therapies. Prog Biophys Mol Biol. 2021;159:118–125. doi: 10.1016/j.pbiomolbio.2020.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pbiomolbio.2020.06.001</ArticleId>
            <ArticleId IdType="pubmed">32565182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins N, Gilbert M, Kumar M, McNamara JW, Daly P, Koch SE, Conway G, Effat M, Woo JG, Sadayappan S, Rubinstein J. Probenecid improves cardiac function in patients with heart failure with reduced ejection fraction in vivo and cardiomyocyte calcium sensitivity in vitro. J Am Heart Assoc. 2018;7(2):e007148. doi: 10.1161/JAHA.117.007148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.117.007148</ArticleId>
            <ArticleId IdType="pmc">PMC5850150</ArticleId>
            <ArticleId IdType="pubmed">29331959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubinstein J, Woo JG, Garcia AM, Alsaied T, Li J, Lunde PK, Moore RA, Laasmaa M, Sammons A, Mays WA, Miyamoto SD, Louch WE, Veldtman GR. Probenecid improves cardiac function in subjects with a fontan circulation and augments cardiomyocyte calcium homeostasis. Pediatr Cardiol. 2020;41(8):1675–1688. doi: 10.1007/s00246-020-02427-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00246-020-02427-7</ArticleId>
            <ArticleId IdType="pmc">PMC7704717</ArticleId>
            <ArticleId IdType="pubmed">32770262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang MA, Solomon DH. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71(9):994–1004. doi: 10.1016/j.jacc.2017.12.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2017.12.052</ArticleId>
            <ArticleId IdType="pmc">PMC5911395</ArticleId>
            <ArticleId IdType="pubmed">29496000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15(1):79–87. doi: 10.1023/A:1011119003788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1011119003788</ArticleId>
            <ArticleId IdType="pubmed">11504167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol. 2012;12(1):1–9. doi: 10.1007/s12012-011-9145-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12012-011-9145-8</ArticleId>
            <ArticleId IdType="pubmed">21938493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE, Olson JJ, Troughton RW. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(1):40–56. doi: 10.1016/j.echo.2014.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.echo.2014.09.009</ArticleId>
            <ArticleId IdType="pubmed">25559474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers J, Buchanan N, Walsh D, Kraemer M, McAuley P, Hamilton-Wessler M, Froelicher VF. Comparison of the ramp versus standard exercise protocols. J Am Coll Cardiol. 1991;17(6):1334–1342. doi: 10.1016/S0735-1097(10)80144-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-1097(10)80144-5</ArticleId>
            <ArticleId IdType="pubmed">2016451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson PD, Arena R, Riebe D. Pescatello LS; American College of Sports Medicine. ACSM's new preparticipation health screening recommendations from ACSM's guidelines for exercise testing and prescription, ninth edition. Curr Sports Med Rep. 2013;12(4):215–217. doi: 10.1249/JSR.0b013e31829a68cf.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/JSR.0b013e31829a68cf</ArticleId>
            <ArticleId IdType="pubmed">23851406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–1255. doi: 10.1016/S0735-1097(00)00531-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-1097(00)00531-3</ArticleId>
            <ArticleId IdType="pubmed">10758967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343. doi: 10.3109/07853890109002087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07853890109002087</ArticleId>
            <ArticleId IdType="pubmed">11491192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gould AL. Sample size re-estimation: recent developments and practical considerations. Stat Med. 2001;20(17-18):2625–2643. doi: 10.1002/sim.733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.733</ArticleId>
            <ArticleId IdType="pubmed">11523073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felker GM, Solomon SD, McMurray JJV, et al.  Effects of omecamtiv mecarbil on symptoms and health-related quality of life in patients with chronic heart failure: results from the COSMIC-HF study. Circ Heart Fail. 2020;13(12):e007814. doi: 10.1161/CIRCHEARTFAILURE.120.007814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007814</ArticleId>
            <ArticleId IdType="pmc">PMC7742205</ArticleId>
            <ArticleId IdType="pubmed">33176437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8(4):329–340. doi: 10.1016/j.jchf.2019.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchf.2019.12.001</ArticleId>
            <ArticleId IdType="pubmed">32035892</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
